Is Naproxen Good for Sciatica? What Evidence Shows

Naproxen provides a real but modest benefit for sciatica pain, with the best available trial showing it reduced leg pain by about half a point on a ten-point scale compared to placebo. That is a statistically measurable difference, but not the kind of dramatic relief most people hope for when they reach for an over-the-counter painkiller. The story gets more interesting when you look at why the benefit is so limited, how naproxen stacks up against other options, and what its particular safety advantages are over rival anti-inflammatory drugs.

What the Largest Naproxen-Specific Sciatica Trial Found

For years, the evidence on naproxen for sciatica was borrowed from broader studies of NSAIDs as a class. A dedicated randomized trial changed that. In this multicenter, double-blind, placebo-controlled study, patients with sciatica took naproxen or placebo for ten days and tracked their daily leg pain on a zero-to-ten scale. Naproxen came out ahead, but the adjusted difference was only about half a point. Over the full treatment period, the average gap widened slightly to about 0.6 points.¹

To put that in practical terms, the researchers calculated how many people would need to take naproxen for one person to achieve at least a 30 percent improvement in pain. That number was about ten. For a 50 percent improvement, roughly 21 people needed treatment for one to benefit beyond what placebo achieved.¹ Those are not encouraging numbers if you are the one in pain, but they do confirm the drug is not inert. The effect on back pain and disability scores was smaller and did not clearly separate from placebo.

The trial’s importance lies partly in the fact that it tested naproxen alone, at a standard dose, in people specifically diagnosed with sciatica rather than garden-variety low back pain. A separate meta-analysis that evaluated individual NSAIDs rated the evidence for naproxen in low back pain with nerve root involvement as “conclusive to be confirmed,” which is a cautious way of saying the signal is real but not yet bulletproof.²

What Broader Reviews of NSAIDs Say About Sciatica

When researchers have pooled trials of various NSAIDs against placebo for sciatica, the overall picture is underwhelming. A Cochrane systematic review that combined three trials involving over 900 patients found that NSAIDs and placebo produced nearly the same reduction in pain scores. On a zero-to-100 pain scale, the pooled difference was less than five points, and the confidence interval crossed zero, meaning the result could have been due to chance.³

One brighter spot in that same review: when researchers looked at “global improvement,” a broader measure that asks patients whether they feel generally better, NSAIDs showed a small but statistically significant edge over placebo. Patients taking NSAIDs were roughly 14 percent more likely to report overall improvement. On disability, though, NSAIDs did not separate from placebo in the single trial that measured it.³

The quality of the underlying evidence was rated low to very low, which reflects not just the trial results but the small number of trials, high variability between them, and methodological limitations. So even the conclusions we do have come with wide error bars. Still, the direction of the findings is consistent: NSAIDs offer some benefit for how patients feel overall, but the raw pain-score improvement is modest at best.

Why an Anti-Inflammatory Drug Barely Dents Nerve Pain

Sciatica often starts with inflammation. A herniated disc presses on or irritates a nerve root, triggering an inflammatory cascade. Immune cells flood the area, and molecules like TNF-alpha ramp up, sensitizing nearby nerve fibers. In the early phase, that inflammatory soup is a major driver of pain. This is where NSAIDs like naproxen should shine, because they block the enzymes that produce prostaglandins, key mediators of inflammation and pain signaling.

The problem is that sciatica rarely stays purely inflammatory. Within weeks, the nerve root itself can become damaged or dysfunctional, and the pain shifts from inflammatory to neuropathic. Neuropathic pain arises from the nerve itself misfiring, and prostaglandin-blocking drugs do very little to address that. A BMJ systematic review made this point explicitly, noting that it would be reasonable to test NSAIDs in patients with acute sciatica, while chronic sciatica with a neuropathic component might respond better to drugs designed for nerve pain, like anticonvulsants or certain antidepressants.⁴

This distinction matters for anyone deciding whether naproxen is worth trying. If your sciatica started recently and the pain is sharp, throbbing, and clearly tied to movement or position, there is a reasonable chance inflammation is still the main culprit and naproxen could take some of the edge off. If you have had symptoms for months and the pain has evolved into burning, tingling, or electric-shock sensations, the inflammatory window may have closed, and naproxen is less likely to help.

Naproxen’s Cardiovascular Edge Over Other NSAIDs

If the pain-relief case for naproxen is modest, its safety profile is where it distinguishes itself from the NSAID pack. The cardiovascular risk of NSAIDs has been a concern since the early 2000s, but not all NSAIDs carry the same degree of risk. Naproxen consistently comes out looking better than its competitors on heart-related outcomes. The balance of evidence suggests that cardiovascular risk tracks with how selectively a drug blocks the COX-2 enzyme, and naproxen’s low selectivity for COX-2 translates to lower cardiovascular risk than other NSAIDs.⁵

The largest head-to-head trial, known as PRECISION, randomized over 24,000 arthritis patients to celecoxib, naproxen, or ibuprofen and tracked cardiovascular events for years. The rates of major cardiovascular events were similar across all three drugs, hovering between roughly 2.3 and 2.7 percent.⁶ That trial was designed primarily to test whether celecoxib was no worse than the others, and it was. But other analyses paint a clearer picture of naproxen’s advantage. A comprehensive review found that compared to placebo, diclofenac significantly raised the risk of vascular events while naproxen did not. The European Medicines Agency has stated that naproxen appears to carry the lowest cardiovascular risk among all NSAIDs.⁷

For someone who needs an NSAID and has cardiovascular risk factors like high blood pressure or a history of heart disease, naproxen is generally considered the safer choice. That does not mean it is risk-free, but the relative advantage is meaningful.

Stomach and Kidney Risks Worth Knowing About

Naproxen’s friendlier profile for the heart does not extend to the gut. All NSAIDs, naproxen included, can cause stomach ulcers and gastrointestinal bleeding. A pooled analysis of two naproxen clinical trials found that the risk of developing an ulcer climbed with the number of risk factors a person had (older age, prior ulcer history, concurrent use of aspirin or blood thinners). But even among patients with none of those risk factors, about a quarter still developed an ulcer on endoscopy.⁸ That is a sobering finding, because most of those ulcers were asymptomatic and would not have been caught without the scope. It underscores that GI risk is not limited to people who “feel” stomach trouble.

The Cochrane review on NSAIDs for sciatica also flagged adverse events. Patients taking NSAIDs were about 40 percent more likely to experience side effects than those on placebo.³ Most of these were GI complaints, not catastrophic events, but the elevated risk is real and gets worse with longer use, higher doses, or combinations with other medications.

Kidney effects are another consideration, especially with prolonged use. NSAIDs work by suppressing prostaglandins, which are not just involved in pain. In the kidneys, prostaglandins help maintain blood flow through the filtering units. When you block them, renal blood flow can drop, and in vulnerable people this can tip over into acute kidney injury. Medical literature links chronic NSAID use to kidney damage particularly in people who already take multiple medications or have underlying heart or liver conditions.⁹ Short courses of naproxen for a sciatica flare are unlikely to cause kidney problems in an otherwise healthy person, but the risk rises quickly if you have reduced kidney function, are dehydrated, or take blood pressure medications.

Gabapentin and Pregabalin Are Not Better

Faced with naproxen’s limited performance, many clinicians and patients turn to gabapentinoids, drugs specifically designed for nerve pain. The logic seems sound: if sciatica involves a misfiring nerve, why not use a nerve-pain drug? The evidence, however, is discouraging. A systematic review and meta-analysis of gabapentin and pregabalin for sciatica found that pregabalin showed no statistically significant difference from placebo in leg pain at two weeks, eight weeks, or even at six and twelve months. Gabapentin had a slight edge at two weeks in one study, but the benefit did not hold up consistently, and the overall conclusion was that neither drug’s effect was superior to placebo.¹⁰

This is a genuinely frustrating finding for the field. The drugs designed for neuropathic pain do not work well for sciatica-related nerve pain, and the drugs designed for inflammatory pain work only modestly. It suggests that sciatica occupies an awkward middle ground between inflammation and nerve dysfunction, and no single class of drug addresses both components adequately. It also means that naproxen’s modest benefit, while disappointing in absolute terms, is not dramatically worse than the alternatives. Much of sciatica management still revolves around time, physical therapy, and epidural steroid injections for more severe cases.

Where Naproxen Fits in Treatment Guidelines

Despite the middling trial results, naproxen and other NSAIDs remain embedded in clinical guidelines for low back pain and sciatica. Multiple professional organizations recommend NSAIDs as first-line pharmacological therapy for acute or subacute low back pain, and as the sole first-line drug class for chronic low back pain.¹¹ The reasoning is partly practical: among the available options, NSAIDs have the best-studied risk-benefit ratio, even if that ratio is not impressive. Opioids carry addiction risk, muscle relaxants cause sedation, and gabapentinoids, as discussed, barely outperform placebo for sciatica.

The guideline language is worth paying attention to. Recommendations for NSAIDs in back pain are stronger than for sciatica specifically. When sciatica is the primary complaint rather than back pain, the evidence base thins out, and clinicians often treat empirically based on the overlap between the two conditions. Naproxen’s position in this landscape is that of a reasonable first try: widely available, inexpensive, relatively safe in the short term, and supported by at least some evidence of benefit. It is not the answer to sciatica, but it remains one of the better-supported early steps.

Practical Considerations for Taking Naproxen During a Sciatica Episode

If you decide to use naproxen for a sciatica flare, timing matters. The evidence, both from mechanism and from trial data, suggests that naproxen is most likely to help during the acute inflammatory phase, usually the first few weeks after symptoms start. The naproxen-specific trial used a ten-day treatment course, and the drug’s advantage over placebo emerged within that window.¹ Taking naproxen for months on end in hopes of addressing chronic sciatica is unlikely to add benefit and progressively increases the risk of GI, kidney, and cardiovascular side effects.

Over-the-counter naproxen sodium is typically dosed at 220 mg per tablet, with label directions allowing up to three tablets in 24 hours. Prescription-strength doses go higher. For sciatica specifically, there is no evidence that higher doses produce proportionally better pain relief, but they do increase side effect risk. Taking the lowest effective dose for the shortest duration is standard advice from every major guideline and remains sensible here.

Taking naproxen with food or a full glass of water can reduce stomach irritation. If you are on blood thinners, have had a stomach ulcer, or take blood pressure medication, talk to a pharmacist or doctor before starting naproxen, because the drug interactions in those combinations can be serious. And if your sciatica has not improved after a week or two of naproxen, continuing indefinitely is not likely to change the picture. That is the point to explore other options, whether physical therapy, epidural injections, or further investigation into what is compressing the nerve.

The Placebo Response in Sciatica Trials

One reason naproxen’s benefit looks small in trials is that the placebo group tends to improve substantially on its own. Sciatica has a strong natural history of improvement. Most episodes, even severe ones, resolve or significantly ease within six to twelve weeks regardless of treatment. When placebo groups are already getting better, the bar for a drug to show a measurable advantage is high. The Cochrane review noted this implicitly: the pooled pain difference between NSAIDs and placebo was tiny not because NSAIDs did nothing, but because placebo groups improved almost as much.³

This does not mean naproxen is useless in practice. Outside a trial, a person does not know whether they are in the group that would have improved without medication or the group that needed the extra push. Even a modest average benefit can translate to meaningful relief for the subset of patients who happen to respond. The honest framing is that naproxen helps some people with acute sciatica, the average effect is small, and we cannot reliably predict who will benefit most. For a cheap, accessible, short-course drug with a well-understood safety profile, that is a reasonable proposition, if not a particularly exciting one.